The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,028.00
Bid: 12,012.00
Ask: 12,016.00
Change: -268.00 (-2.18%)
Spread: 4.00 (0.033%)
Open: 12,226.00
High: 12,266.00
Low: 11,988.00
Prev. Close: 12,296.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AstraZeneca Gets Positive EU Committee Opinion On Forixga And Fasenra

Mon, 01st Jul 2019 08:56

(Alliance News) - AstraZeneca PLC on Monday said it has received positive opinions in the EU for drugs Forixga and Fasenra.

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended changing Forixga's EU marketing authorisation in type-2 diabetics to include cardiovascular outcomes data from the drug maker's phase 2 Declare-TIMI 58 trial.

The trial showed Forixga produced a statistically significant drop in hospitalisation for heart failure of cardiovascular death compared to a placebo. Moreover, patients taking Forixga also had a lower chance of major adverse cardiovascular events - though not at a statistically significant level.

"We are pleased with this positive opinion for the cardiovascular outcomes and renal data for Forxiga and this recommendation acknowledges that even more people with type-2 diabetes could benefit from this medicine," said Mene Pangalos, executive vice president of BioPharmaceuticals Research & Development at Astra.

Separately, FTSE 100 drug maker Astra said the CHMP also gave a positive opinion on adding a self-administration option to asthma drug Fasenra and a new delivery method of a "pre-filled, single-use auto-injector" - known as the Fasenra pen - to product information in the EU.

Fasenra treats severe, eosinophilic asthma - a type of asthma where patients produce too many white blood cells called eosinophils, which cause inflammation of the lungs.

Astra said the committee's opinion can be put in place without requiring a decision from the European Commission because of the type of label variation.

Pangolas also commented on the Fasenra opinion, saying: "Fasenra is the only respiratory biologic medicine that can be administered every eight weeks after the initial loading-dose period, and this positive opinion means we are closer to offering Fasenra in a way that is even more convenient for many patients. We hope self-administration and the Fasenra pen will play important roles in helping physicians make treatment with biologic medicines accessible to more people with severe eosinophilic asthma."

Shares in Astra were up 0.4% at 6,466.00 pence on Monday morning.

More News
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more
26 Dec 2023 21:26

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
26 Dec 2023 21:00

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
26 Dec 2023 19:41

Wall Street gains on final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
22 Dec 2023 08:47

AstraZeneca, Ionis get US FDA nod for Wainua in "important milestone"

(Alliance News) - AstraZeneca PLC and Ionis Pharmaceuticals Inc on Friday celebrated the news that their drug eplontersen was approved by the US Food & Drug Administration.

Read more
22 Dec 2023 07:50

LONDON BRIEFING: UK on brink of recession as economy contracts in Q3

(Alliance News) - Stocks in London are likely to open lower on Friday, with investors feeling frosty ahead of a US inflation print this afternoon, amid sobering UK economic growth data.

Read more
22 Dec 2023 07:17

AstraZeneca gets FDA green light for nerve disease treatment

(Sharecast News) - The US Food and Drug Administration has approved the Wainua nerve disease treatment jointly developed by AstraZeneca and Ionis Pharmaceuticals.

Read more
19 Dec 2023 19:56

US adds 13 companies in China to Unverified List

WASHINGTON, Dec 19 (Reuters) - The United States has added 13 companies in China to a list of entities receiving U.S. exports that officials have been unable to inspect, according to a government notice posted on Tuesday.

Read more
15 Dec 2023 17:14

London stocks log weekly gains as cenbank fest ends

FTSE 100 down 1.0%, FTSE 250 off -0.3%

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
13 Dec 2023 17:07

UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision

UK economy shrinks by 0.3% in October

*

Read more
12 Dec 2023 16:00

London close: Stocks slip as investors digest US inflation

(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.

Read more
12 Dec 2023 12:07

London midday: FTSE still firmer ahead of US inflation print

(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.